Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Healthcare Stocks That Will Generate Strong Returns: Stryker Corporation (SYK) and More

Page 1 of 2

After the enforcement of the Patient Protection and Affordable Care Act (PPACA) or Obamacare, investors are boosting their positions in Healthcare stocks covering insurance providers, drug-makers and hospitals. PPACA aims at giving every US citizen health care insurance by 2014. Eventually, what that means is, it will also create new revenue streams for the Healthcare companies. I believe that the health-care sector will significantly grow due to the increase in Healthcare spending.

Stryker CorporationJust to give an idea of its impact, this spending will increase by ~70% to $4.8 trillion by 2021 from the current level of $2.8 trillion. Keeping this in mind, I have screened three healthcare stocks that will benefit in the long term via Obamacare. One more reason for my affinity towards these stocks is that they have strong business fundamentals and have the potential to generate returns via both domestic and international business expansion.

Let’s have a detailed look at each of these stocks

Stryker Corporation (NYSE:SYK)

Stryker declared its fourth quarter and full year results for 2012 last month. It posted full year net income of ~$2.7 billion, which was up by around 4% y/y. The topline drivers for this growth were its Neurotechnology and Spine business segments, that grew by 9.7% y/y to ~$414 million. For 2013, the company is projecting a sales growth of 3%-5.5%.

Emerging markets have been a cause for pain for Stryker. The emerging markets currently contribute only 6% to its overall sales. In order to boost up its overall market share especially in China, Stryker has agreed to acquire Hong Kong’s Trauson Holdings for $764 million. Trauson had reported $60 million of sales in 2011. Orthopedic sales in China will grow massively to $2.7 billion by 2015 and $4.5 billion by 2017. Via this acquisition, Stryker will take advantage of this growth opportunity in the coming years. This acquisition will further bolster its revenue by ~4% y/y in 2013.

Focusing on investors

Stryker’s solid balance sheet and its ability to generate huge free cash flow ($1123 million in 2012) shall allow the company to pay higher dividends, and to go for acquisitions and buybacks of its shares. Stryker has recently announced that it will buyback additional shares worth $405 million in the coming years, though the management has not yet declared the price and timing of this buyback plan.

Expansion in its global market share due to the recent acquisition along with its buyback strategy will bring long-term revenue growth for Stryker and therefore, I recommend a buy for Stryker Corporation.

UnitedHealth Group Inc. (NYSE:UNH)

UnitedHealth Group came up with solid 4Q12 results. The total revenue for the quarter grew drastically by ~11% to $28.8 billion y/y. Growth in Q4 revenue was backed by consistent expansion in its care management, Medicare, and international business. The company also saw 6% growth in its membership, which resulted in around 83 million customers.

During the fourth quarter, UnitedHealth Group had bought 65% of the Brazilian company- Amil Participacoes for $3.5 billion. This investment has helped UnitedHealth group to boost up its international revenue to $1 billion during the 4Q. Keeping the potential growth prospects in mind, UnitedHealth Group will increase its holding in Amil Participacoes by 25% during the first couple of quarters of 2013. Via this investment, I expect tremendous growth opportunities for the company in the future.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!